Voyager Therapeutics, Inc. – NASDAQ:VYGR
Voyager Therapeutics stock price today
$3.54
-2.2
-38.33%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Voyager Therapeutics stock price monthly change
-34.55%
month
Voyager Therapeutics stock price quarterly change
-34.55%
quarter
Voyager Therapeutics stock price yearly change
-34.02%
year
Voyager Therapeutics key metrics
Market Cap | 307.54M |
Enterprise value | N/A |
P/E | -6.71 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 3.73 |
Price/Book | 5.18 |
PEG ratio | -0.18 |
EPS | -0.01 |
Revenue | 119.04M |
EBITDA | -12.49M |
Income | -3.04M |
Revenue Q/Q | -87.03% |
Revenue Y/Y | -21.26% |
Profit margin | -56.6% |
Oper. margin | -62% |
Gross margin | 0.87% |
EBIT margin | -62% |
EBITDA margin | -10.49% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVoyager Therapeutics stock price history
Voyager Therapeutics stock forecast
Voyager Therapeutics financial statements
Average Price Target
$18
Potential upside: 408.47%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 4.85M | -22.20M | -457.61% |
|---|---|---|---|
| Sep 2023 | 4.61M | -25.90M | -561.36% |
| Dec 2023 | 90.06M | 56.39M | 62.62% |
| Mar 2024 | 19.51M | -11.33M | -58.05% |
| 2024-02-28 | -0.59 | 1.25 |
|---|
| Jun 2023 | 315536000 | 116.51M | 36.92% |
|---|---|---|---|
| Sep 2023 | 294653000 | 118.43M | 40.19% |
| Dec 2023 | 351281000 | 114.96M | 32.73% |
| Mar 2024 | 469592000 | 128.70M | 27.41% |
| Jun 2023 | -835K | -24.66M | 1.54M |
|---|---|---|---|
| Sep 2023 | -21.05M | -158.30M | 331K |
| Dec 2023 | -25.86M | 26.83M | 2.56M |
| Mar 2024 | 58.76M | -96.06M | 112.85M |
Voyager Therapeutics alternative data
| Aug 2023 | 125 |
|---|---|
| Sep 2023 | 125 |
| Oct 2023 | 125 |
| Nov 2023 | 125 |
| Dec 2023 | 125 |
| Jan 2024 | 125 |
| Feb 2024 | 125 |
| Mar 2024 | 162 |
| Apr 2024 | 162 |
| May 2024 | 162 |
| Jun 2024 | 162 |
| Jul 2024 | 162 |
Voyager Therapeutics other data
19.17%
-38.59%
of VYGR is owned by hedge funds
44
-25
7.35M
-15.50M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 3809 |
| Feb 2024 | 0 | 24730 |
| Apr 2024 | 0 | 13472 |
| Oct 2024 | 0 | 5999 |
| Dec 2024 | 0 | 6500 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SWARTZ ROBIN officer: COO&CBO | Common Stock | 6,500 | $5.65 | $36,725 | ||
Sale | FAHEY SANDELL JACQUELYN officer: Chief Legal Officer | Common Stock | 5,999 | $5.82 | $34,914 | ||
Sale | SWARTZ ROBIN officer: Chief Operating Officer | Common Stock | 1,357 | $9.88 | $13,407 | ||
Sale | SANDROCK ALFRED director, officer: President an.. | Common Stock | 12,115 | $9.86 | $119,454 | ||
Sale | SWARTZ ROBIN officer: Chief Operating Officer | Common Stock | 3,966 | $7.45 | $29,547 | ||
Sale | SANDROCK ALFRED director, officer: President an.. | Common Stock | 13,033 | $7.46 | $97,226 | ||
Sale | PFREUNDSCHUH PETER P. officer: Chief Fi.. | Common Stock | 3,764 | $7.46 | $28,079 | ||
Sale | CARTER TODD ALFRED officer: Chief Scientific Officer | Common Stock | 3,365 | $7.47 | $25,137 | ||
Sale | CARTER TODD ALFRED officer: Chief Scientific Officer | Common Stock | 602 | $7.68 | $4,623 | ||
Sale | SWARTZ ROBIN officer: Chief Operating Officer | Common Stock | 2,543 | $7.15 | $18,182 |
| Patent |
|---|
Grant Filling date: 16 Oct 2018 Issue date: 6 Sep 2022 |
Application Filling date: 24 Jul 2020 Issue date: 1 Sep 2022 |
Application Filling date: 29 Apr 2020 Issue date: 4 Aug 2022 |
Application Filling date: 22 Mar 2022 Issue date: 7 Jul 2022 |
Application Filling date: 6 Dec 2021 Issue date: 23 Jun 2022 |
Application Filling date: 1 Jun 2021 Issue date: 23 Jun 2022 |
Application Filling date: 29 Apr 2020 Issue date: 2 Jun 2022 |
Application Filling date: 4 Nov 2021 Issue date: 26 May 2022 |
Grant Filling date: 28 Apr 2017 Issue date: 10 May 2022 |
Application Filling date: 8 Oct 2021 Issue date: 28 Apr 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. G. Andre Turenne (1974) Advisor | $873,480 |
| Mr. Robert W. Hesslein (1953) Senior Vice President & Gen. Counsel | $580,650 |
Mr. Michael J. Higgins M.B.A. (1962) Interim Chief Executive Officer, Pres & Chairman | $90,000 |
| Dr. Glenn F. Pierce M.D., Ph.D. (1956) Independent Director, Interim Chief Scientific Officer & Chief Medical Officer | $51,500 |
| Dr. Steven M. Paul M.D. (1951) Executive Science Advisor & Director | $44,000 |
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
The 'Undercovered' Dozen From June 1-6
Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
3 Biotech Names Under $10 I Own
Voyager Therapeutics' Strategic Partnerships And TRACER Technology - Speculative Buy
August MDA Breakout Stocks Week 32 - 2023: High-Frequency Gainers To Give You An Edge
August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge
Voyager: Preclinical Company With Major Big Pharma Deals
-
What's the price of Voyager Therapeutics stock today?
One share of Voyager Therapeutics stock can currently be purchased for approximately $3.54.
-
When is Voyager Therapeutics's next earnings date?
Unfortunately, Voyager Therapeutics's (VYGR) next earnings date is currently unknown.
-
Does Voyager Therapeutics pay dividends?
No, Voyager Therapeutics does not pay dividends.
-
How much money does Voyager Therapeutics make?
Voyager Therapeutics has a market capitalization of 307.54M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 511.16% to 250.01M US dollars. Voyager Therapeutics earned 132.33M US dollars in net income (profit) last year or $1.25 on an earnings per share basis.
-
What is Voyager Therapeutics's stock symbol?
Voyager Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "VYGR".
-
What is Voyager Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Voyager Therapeutics?
Shares of Voyager Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Voyager Therapeutics's key executives?
Voyager Therapeutics's management team includes the following people:
- Mr. G. Andre Turenne Advisor(age: 51, pay: $873,480)
- Mr. Robert W. Hesslein Senior Vice President & Gen. Counsel(age: 72, pay: $580,650)
- Mr. Michael J. Higgins M.B.A. Interim Chief Executive Officer, Pres & Chairman(age: 63, pay: $90,000)
- Dr. Glenn F. Pierce M.D., Ph.D. Independent Director, Interim Chief Scientific Officer & Chief Medical Officer(age: 69, pay: $51,500)
- Dr. Steven M. Paul M.D. Executive Science Advisor & Director(age: 74, pay: $44,000)
-
How many employees does Voyager Therapeutics have?
As Jul 2024, Voyager Therapeutics employs 162 workers.
-
When Voyager Therapeutics went public?
Voyager Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 11 Nov 2015.
-
What is Voyager Therapeutics's official website?
The official website for Voyager Therapeutics is voyagertherapeutics.com.
-
Where are Voyager Therapeutics's headquarters?
Voyager Therapeutics is headquartered at 75 Sidney Street, Cambridge, MA.
-
How can i contact Voyager Therapeutics?
Voyager Therapeutics's mailing address is 75 Sidney Street, Cambridge, MA and company can be reached via phone at 857 259 5340.
-
What is Voyager Therapeutics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Voyager Therapeutics in the last 12 months, the avarage price target is $18. The average price target represents a 408.47% change from the last price of $3.54.
Voyager Therapeutics company profile:
Voyager Therapeutics, Inc.
voyagertherapeutics.comExchange:
NASDAQ
Full time employees:
162
Industry:
Biotechnology
Sector:
Healthcare
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
75 Sidney Street
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001640266
ISIN: US92915B1061
CUSIP: 92915B106
